CME Compete™
Staying in the Lead
Navigating the Changing Course of Sickle Cell Disease Management
Meeting slides
Suggested Readings
A critical review of therapeutic interventions in sickle cell disease: progress and challenges.
Ala C, et al. Arch Pharm (Weinheim). 2024;357(11):e2400381
Advances in pharmacotherapy for sickle cell disease: what is the current state of play?
Alan S, Kanter J. Expert Opin Pharmacother. 2024;25(10):1325-1334.
Current state of gene therapy in sickle cell disease.
Tang MS, Shan H. Vox Sang. 2024;119(6):521-528.
A standardized metric to define a successful transition from pediatric to adult care in sickle cell disease.
Pollock G, Curtis S. Blood Adv. 2025;9(18):4622-4623.
Psychosocial challenges of persons with sickle cell anemia: a narrative review.
Essien EA, et al. Medicine (Baltimore). 2023;102(47):e36147.
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.
van Dijk MJ, et al. Blood Adv. 2023;7(24):7539-7550.
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomized, placebo-controlled trial.
Idowu M, et al. Lancet Haematol. 2025;12(1):e35-e44.
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, et al. Blood Adv. 2024;8(16):4459-4475.
Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks.
Delicou S, et al. Blood. 2024;144 (suppl 1):179.
Linked Resources
PRACTICE GUIDELINES & CONCENSUS STATEMENTS
Evidence-based management of sickle cell disease: expert panel report, 2014.
National Heart, Lung, and Blood Institute (NHLBI).
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.
Brandow AM, et al. Blood Adv. 2020;4(12):2656–2701.
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.
Kanter J, et al. Blood Adv. 2021;5(18):3668-3689.
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
Chou ST, et al. Blood Adv. 2020;4(2): 327–355.
CLINICAL PRACTICE TOOLS AND RESOURCES
Clinician Pocket Guide
American Society of Hematology Clinical Resources
PATIENT RESOURCES AND ADVOCACY ORGANIZATIONS
Sickle Cell Speaks
Be the Spark - The Foundation for Sickel Cell Disease Research
Sickle Cell Disease Association of America
The Sickle Cell Consortium
Sickle Cell 101
The William E. Proudford Sickle Cell Fund, Inc.
The Foundation for Sickle Cell Disease Research
Related activities
Webcast
1.50 AMA PRA
Staying in the Lead
Navigating the Changing Course of Sickle Cell Disease Management
| Faculty: | Lakiea Bailey, PhD; Modupe Idowu, MD; Nirmish Shah, MD |
| Release: | 12/05/2025 |
| Expiration: | 01/09/2026 |
